Cargando…

Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients

Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphoklne‐activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)‐resistant human tum...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyama, Shohei, Ebihara, Tsugio, Fukao, Katashi, Osuga, Toshiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1989
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917700/
https://www.ncbi.nlm.nih.gov/pubmed/2498249
http://dx.doi.org/10.1111/j.1349-7006.1989.tb02283.x
_version_ 1783317269106917376
author Koyama, Shohei
Ebihara, Tsugio
Fukao, Katashi
Osuga, Toshiaki
author_facet Koyama, Shohei
Ebihara, Tsugio
Fukao, Katashi
Osuga, Toshiaki
author_sort Koyama, Shohei
collection PubMed
description Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphoklne‐activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)‐resistant human tumor cells, Daudi, as well as NK‐sensitive, K562 cells. LAK cells were generated from both normal and gastric cancer patients' PBL. However, LAK cell activities induced by rIL 2 or TCGF decreased with the progress of the tumor growth. In addition, TCGF‐induced LAK cell activities were found to be lower than the rIL 2‐indnced LAK cell activities. Different mechanisms may be involved in the decreases of the rIL 2‐induced and TCGF‐induced LAK cell activities. This study further demonstrates that the cell types involved are also heterogeneous, as determined by phenotypic characteristics. The LAK‐effector cell type was analyzed by two‐color flow cytometry. RIL 2‐induced LAK cells showed increased proportions of CD4(±)Leu 8(‐) and Leu 7(±)CD16(‐), and a decreased proportion of CD8(±)CD11(‐) cells, which are believed to be associated with killer T cell functions. In contrast, TCGF‐induced LAK cells revealed significantly increased proportions of CD8(±)CD11(‐)and CD4(±)Leu 8(‐) cells, and a decreased proportion of Leu 7(±)CD16(‐) cells. Thus, LAK cells with different surface phenotypes were induced by the cultivations with rIL 2 and with TCGF.
format Online
Article
Text
id pubmed-5917700
institution National Center for Biotechnology Information
language English
publishDate 1989
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59177002018-05-11 Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients Koyama, Shohei Ebihara, Tsugio Fukao, Katashi Osuga, Toshiaki Jpn J Cancer Res Article Fourteen days' culture of human peripheral blood lymphocytes (PBL) with recombinant interleukin 2 (rIL 2) or T cell growth factor (TCGF) results in the generation of lymphoklne‐activated killer (LAK) effector cells which have the unique property of lysing natural killer (NK)‐resistant human tumor cells, Daudi, as well as NK‐sensitive, K562 cells. LAK cells were generated from both normal and gastric cancer patients' PBL. However, LAK cell activities induced by rIL 2 or TCGF decreased with the progress of the tumor growth. In addition, TCGF‐induced LAK cell activities were found to be lower than the rIL 2‐indnced LAK cell activities. Different mechanisms may be involved in the decreases of the rIL 2‐induced and TCGF‐induced LAK cell activities. This study further demonstrates that the cell types involved are also heterogeneous, as determined by phenotypic characteristics. The LAK‐effector cell type was analyzed by two‐color flow cytometry. RIL 2‐induced LAK cells showed increased proportions of CD4(±)Leu 8(‐) and Leu 7(±)CD16(‐), and a decreased proportion of CD8(±)CD11(‐) cells, which are believed to be associated with killer T cell functions. In contrast, TCGF‐induced LAK cells revealed significantly increased proportions of CD8(±)CD11(‐)and CD4(±)Leu 8(‐) cells, and a decreased proportion of Leu 7(±)CD16(‐) cells. Thus, LAK cells with different surface phenotypes were induced by the cultivations with rIL 2 and with TCGF. Blackwell Publishing Ltd 1989-02 /pmc/articles/PMC5917700/ /pubmed/2498249 http://dx.doi.org/10.1111/j.1349-7006.1989.tb02283.x Text en
spellingShingle Article
Koyama, Shohei
Ebihara, Tsugio
Fukao, Katashi
Osuga, Toshiaki
Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
title Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
title_full Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
title_fullStr Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
title_full_unstemmed Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
title_short Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients
title_sort differential activation of lymphokine‐activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or t‐cell growth factor in gastric cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5917700/
https://www.ncbi.nlm.nih.gov/pubmed/2498249
http://dx.doi.org/10.1111/j.1349-7006.1989.tb02283.x
work_keys_str_mv AT koyamashohei differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients
AT ebiharatsugio differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients
AT fukaokatashi differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients
AT osugatoshiaki differentialactivationoflymphokineactivatedkillercellswithdifferentsurfacephenotypesbycultivationwithrecombinantinterleukin2ortcellgrowthfactoringastriccancerpatients